Alberto Arranz

Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV

Federico Pulido, José Ramón Arribas, Rafaël Delgado et al. · AIDS · 2008 · 154 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Lopinavir/Ritonavir as Single-Drug Therapy for Maintenance of HIV-1 Viral Suppression

José Ramón Arribas, Federico Pulido, Rafaël Delgado et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2005 · 149 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Lopinavir-Ritonavir Monotherapy Versus Lopinavir-Ritonavir and 2 Nucleosides for Maintenance Therapy of HIV: 96-Week Analysis

José Ramón Arribas, Rafaël Delgado, Alberto Arranz et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2009 · 108 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial

Federico Pulido, Esteban Ribera, María Lagarde et al. · Clinical Infectious Diseases · 2017 · 102 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study

Sergio Serrano‐Villar, Javier Martínez‐Sanz, Raquel Ron et al. · The Lancet HIV · 2020 · 70 citations · Full text

Public Health, Immunology, Infectious Diseases +8